Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE is an experimental small molecule belonging to the class of peptides. It contains an amide derived from two or more amino acids and features a benzyl ester group. The compound has not been approved for any indication and there are no clinical trials reported for it. Its mechanism of action is not described in available sources; however, based on its structure as a peptide derivative with an oxirane (epoxide) moiety and carbamoyl substituents, it may be designed as a protease inhibitor or enzyme modulator[1][2]. No information about its developer or manufacturer is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE.